首页> 外文期刊>Brain research >Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
【24h】

Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.

机译:5-HT1A受体激动剂8-OH-DPAT在左旋多巴诱发的运动并发症大鼠模型中的细胞和行为效应。

获取原文
获取原文并翻译 | 示例
           

摘要

5-HT1A autoreceptor stimulation can act to attenuate supraphysiological swings in extracellular dopamine levels following long-term levodopa treatment and may be useful in the treatment and prevention of the motor complications. The purpose of this study was to investigate cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. Two sets of experiments were performed. First, animals were treated with levodopa (50 mg/kg with benserazide 12.5 mg/kg, twice daily), intraperitoneally (i.p.) for 22 days. On day 23, animals received either 8-OH-DPAT (1 mg/kg, i.p.) or 8-OH-DPAT plus WAY-100635 (0.1 mg/kg, i.p) or vehicle with each levodopa dose. In the second set, animals were treated either with levodopa (50 mg/kg, i.p.) plus 8-OH-DPAT (1 mg/kg, i.p.) or levodopa (50 mg/kg, i.p.) plus vehicle, administered twice daily for 22 consecutive days. Our study showed that 8-OH-DPAT plus levodopa both prolonged the duration of the motor response and reduced peak turning. 8-OH-DPAT plus levodopa also decreased the frequency of failures to levodopa. Co-administration of WAY-100635, a 5-HT1A receptor antagonist, with 8-OH-DPAT eliminated the effect of 8-OH-DPAT on motor complications indicating that the observed 8-OH-DPAT responses were probably mediated at the 5-HT1A autoreceptor. Moreover, 8-OH-DPAT plus levodopa significantly reduced hyperphosphorylation of GluR1 at serine 845, which was closely associated with levodopa-induced motor complications.
机译:5-HT1A自身受体刺激可在长期左旋多巴治疗后减轻细胞外多巴胺水平的超生理波动,并可用于治疗和预防运动并发症。这项研究的目的是调查5-HT1A受体激动剂8-OH-DPAT在左旋多巴诱发的运动并发症大鼠模型中的细胞和行为效应。进行了两组实验。首先,腹膜内(i.p.)用左旋多巴(50mg / kg与苄丝肼12.5mg / kg,每天两次)治疗动物22天。在第23天,动物接受8-OH-DPAT(1 mg / kg,腹膜内)或8-OH-DPAT加WAY-100635(0.1 mg / kg,i.p)或赋形剂,每次左旋多巴剂量。在第二组中,用左旋多巴(50 mg / kg,ip)加8-OH-DPAT(1 mg / kg,ip)或左旋多巴(50 mg / kg,ip)加溶媒治疗动物,每天两次连续22天。我们的研究表明,8-OH-DPAT加左旋多巴既延长了运动反应的持续时间,又降低了峰值转弯。 8-OH-DPAT加左旋多巴还可降低左旋多巴失败的频率。 5-HT1A受体拮抗剂WAY-100635与8-OH-DPAT并用可消除8-OH-DPAT对运动并发症的影响,这表明观察到的8-OH-DPAT反应可能是在5-位介导的。 HT1A自身受体。此外,8-OH-DPAT加左旋多巴显着降低了丝氨酸845处GluR1的过度磷酸化,这与左旋多巴诱发的运动并发症密切相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号